The present invention provides an
androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for
hormone-sensitive
cancer, which contain a compound of the formula: wherein, R1 is a
hydrogen atom, a group binding through a
carbon atom, a group binding through a
nitrogen atom, a group binding through an
oxygen atom or a group binding through a
sulfur atom, R2 is a
hydrogen atom, a group binding through a
carbon atom, a group binding through a
nitrogen atom, a group binding through an
oxygen atom or a group binding through a
sulfur atom, R3 is a
hydrogen atom, a
hydrocarbon group which may have
substituent(s), an
acyl group or a heterocyclic group which may have
substituent(s), R4 is a
hydrogen atom, a group binding through a
carbon atom, a group binding through a
nitrogen atom, a group binding through an
oxygen atom or a group binding through a
sulfur atom, and R5 is a cyclic group which may have
substituent(s); or a salt thereof, or its
prodrug.